Annals of pediatric endocrinology & metabolism · 2025
Assessing the ovarian reserve in girls who survived childhood leukemia using anti-Mullerian hormone.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jingrukwong Lalita, Srilanchakon Khomsak, Lauhasurayotin Supanun, Chiengthong Kanhatai
Аннотация
PURPOSE: Acute leukemia is the most common form of malignancy in children; however, there is an absence of data regarding the long-term ovarian reserve of female survivors. The purpose of this investigation was to examine potential discrepancies in anti-Mullerian hormone (AMH) levels among female survivors of pediatric acute leukemia.
METHODS: A cross-sectional study was conducted on female survivors aged 2 to 18 years who completed gonadotoxic chemotherapy sessions at least 1 year prior to evaluation. Based on Tanner staging, the participants were divided into pre-pubertal and pubertal groups. Serum AMH, follicle stimulating hormone (FSH), luteinizing hormone (LH), and estradiol were assessed.
RESULTS: Three of 36 participants demonstrated low AMH levels in comparison to the adjusted age-reference range, whereas all participants had normal FSH and LH levels. However, the correlation between cumulative dose of cyclophosphamide and AMH level was not statistically significant.
CONCLUSION: Measurement of AMH level may not be beneficial in individuals who have received a cumulative dose of cyclophosphamide less than 5,400 mg/m2.
METHODS: A cross-sectional study was conducted on female survivors aged 2 to 18 years who completed gonadotoxic chemotherapy sessions at least 1 year prior to evaluation. Based on Tanner staging, the participants were divided into pre-pubertal and pubertal groups. Serum AMH, follicle stimulating hormone (FSH), luteinizing hormone (LH), and estradiol were assessed.
RESULTS: Three of 36 participants demonstrated low AMH levels in comparison to the adjusted age-reference range, whereas all participants had normal FSH and LH levels. However, the correlation between cumulative dose of cyclophosphamide and AMH level was not statistically significant.
CONCLUSION: Measurement of AMH level may not be beneficial in individuals who have received a cumulative dose of cyclophosphamide less than 5,400 mg/m2.